DiaSorin S.p.A. (DSRLF) Q1 2026 Earnings Call Transcript

DiaSorin said Q1 2026 performance was slightly negative at -3% on a constant-currency basis, hurt by a roughly 25% decline in flu-season volumes. The weakness weighed on molecular diagnostics, especially respiratory multiplex products, though management expects the trend to reverse in the second half of the year. The call signals near-term pressure but not a change in the longer-term outlook.

Analysis

The immediate read-through is not just a weak respiratory quarter; it is a reminder that DiaSorin’s growth mix still has a hidden cyclicality tied to seasonal virology, which makes the multiple vulnerable whenever flu/RSV normalization disappoints. That matters more than the headline decline because platforms with meaningful respiratory exposure can see revenue decelerate faster than consensus models assume, and the operating leverage downside is usually larger than the top-line move.

Second-order, a weak flu season can temporarily favor competitors with heavier non-respiratory mixes or broader consumables pull-through, while also pressuring channel inventory planning into the next quarter. If customers under-order molecular respiratory panels now, the rebound may be delayed rather than simply shifted, creating a more uneven second-half recovery than management implies. That increases the risk that any “second-half normalization” becomes a rolling forecast rather than a real inflection.

The contrarian angle is that this could set up a better entry if the market extrapolates one season into a structural slowdown. Diagnostics names often de-rate quickly on seasonal misses, but the earnings power can reassert once volume elasticity returns; the key variable is whether management can prove that non-respiratory assays are stable enough to offset the flu drag. If not, the stock may need a reset to reflect a lower, more volatile base growth rate rather than a one-off weather event.

Catalyst-wise, the next 4-8 weeks matter for whether Q2 ordering normalizes or channel caution persists. The real risk is that the weaker season bleeds into procurement behavior and inventory destocking, which would push the recovery out to H2 and make any rebound lower quality. Conversely, a sharp pickup in respiratory positivity rates or an easier comp in the second half could force a short-covering move if investors are currently modeling too linear a recovery.

Key Decisions for Investors

• Avoid chasing the first dip: wait 2-4 weeks for evidence of channel normalization before buying DSRLF; if respiratory order trends stabilize, the risk/reward improves from defensive to rebound trade.
• Short-term tactical short in DSRLF against a basket of more diversified diagnostics names for 1-2 months; thesis is multiple compression from seasonality disappointment, with upside limited if management merely reiterates H2 recovery.
• If already long, buy downside protection via 3-6 month puts or put spreads into the next update window; the cleanest risk is a delayed inventory rebound rather than further top-line shock.
• Use any 8-12% post-earnings selloff to accumulate only if non-respiratory revenue proves resilient; otherwise the stock deserves a lower growth multiple for a more volatile mix.